Prelude Therapeutics Incorporated (PRLD)
After hours:
| Previous close | 4.0400 |
| Open | 4.0500 |
| Bid | 3.9000 x 100 |
| Ask | 4.1800 x 100 |
| Day's range | 3.9900 - 4.0700 |
| 52-week range | 1.6600 - 6.8900 |
| Volume | |
| Avg. volume | 68,887 |
| Market cap | 223.527M |
| Beta (5Y monthly) | 1.50 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.0200 |
| Earnings date | 06 May 2024 - 10 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 5.80 |
Simply Wall St.Several Insiders Invested In Prelude Therapeutics Flagging Positive News
It is usually uneventful when a single insider buys stock. However, When quite a few insiders buy shares, as it...
GlobeNewswirePrelude Highlights Continued Strength of Discovery Engine at 2024 AACR Annual Meeting
Highly selective oral SMARCA2 degrader, PRT7732, shows robust anti-tumor activity in vivo as monotherapy and in combination with chemotherapy, at well-tolerated doses Potentially best-in-class CDK9 inhibitor, PRT2527, in Phase 1 development, is highly effective in preclinical hematological models as monotherapy and provides improved depth and duration of response in combination with BTK/BCL2 inhibition Next Generation CDK4/6 Inhibitor, PRT3645, is highly effective in combination with other targe
- GlobeNewswire
Prelude Announces Acceptance of Multiple Preclinical Abstracts at the 2024 AACR Annual Meeting
Posters to highlight highly selective oral SMARCA2 degrader, potentially best-in-class CDK9 inhibitor and next-generation CDK4/6 inhibitorWILMINGTON, Del., March 05, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that three posters with preclinical data on the Company’s highly selective oral SMARCA2 degrader, its potentially best-in-class CDK9 inhibitor and its next-generation CDK4/6 inhibitor, have been acc
